How Analysts Feel About Genocea Biosciences Inc (NASDAQ:GNCA)?

July 17, 2017 - By Vivian Park

 How Analysts Feel About Genocea Biosciences Inc (NASDAQ:GNCA)?

Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage

Among 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genocea Biosciences had 7 analyst reports since August 6, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of GNCA in report on Thursday, August 6 with “Overweight” rating. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Buy” rating given on Tuesday, August 11 by Needham. The firm has “Outperform” rating by FBR Capital given on Monday, October 19. Needham maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Tuesday, October 20. Needham has “Buy” rating and $15 target. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) earned “Buy” rating by Needham on Thursday, September 29. The firm has “Buy” rating given on Thursday, December 17 by UBS. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Overweight” rating given on Thursday, September 29 by PiperJaffray. Below is a list of Genocea Biosciences Inc (NASDAQ:GNCA) latest ratings and price target changes.

The stock decreased 0.61% or $0.03 during the last trading session, reaching $4.91. About 121,811 shares traded. Genocea Biosciences Inc (NASDAQ:GNCA) has risen 67.22% since July 17, 2016 and is uptrending. It has outperformed by 50.52% the S&P500.

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The company has market cap of $141.39 million. The Firm uses its discovery platform, AnTigen Lead Acquisition System , to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. It currently has negative earnings. The Firm has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes.

More notable recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: Fool.com which released: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” on April 01, 2016, also Seekingalpha.com with their article: “Is Genocea On Track To Execute A Lucrative Strategic Partnership In The Near …” published on May 05, 2017, Globenewswire.com published: “Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast …” on April 27, 2017. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) were released by: Globenewswire.com and their article: “Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial” published on January 05, 2017 as well as Zacks.com‘s news article titled: “Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher March 08, 2017” with publication date: March 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: